Lmri.O

Lumexa Imaging Holdings Inc maintains a capital structure characterized by significant leverage, with long-term debt of $876.96 million against total equity of $586.12 million, resulting in a debt-to-equity ratio of 1.5. The company holds $58.83 million in cash and equivalents, leading to a negative net cash position as flagged in the risk assessment. Liquidity is assessed as medium, supported by a current ratio of 1.27, which indicates sufficient short-term assets to cover immediate liabilities but leaves limited buffer for unexpected shocks. The enterprise value to revenue multiple stands at 1.82, while the price-to-book ratio is 1.79, reflecting the market's valuation of the company's tangible assets relative to its debt burden.

Profitability metrics indicate operational challenges, with a net loss of $47.10 million on revenues of $1.02 billion, yielding a negative return on equity of -8.04% and a negative return on assets of -2.67%. The gross profit of $157.57 million suggests a gross margin of approximately 15.4%, which is typical for hardware-intensive medical device manufacturers but leaves limited room for operating expenses. Operating income of $84.45 million demonstrates that the core business generates positive cash flow from operations before interest and taxes, yet the net loss highlights the impact of interest expenses on the high debt load. Free cash flow is negative at -$30.18 million, driven by capital expenditures of $23.48 million exceeding operating cash flow of $17.07 million.

Revenue concentration and geographic exposure details are not provided in the available data, preventing a specific analysis of segment or regional risk. The company's activity is broadly defined as medical devices within the healthcare sector. Without specific segment breakdowns, the revenue base is treated as a consolidated whole, implying that performance is tied to the general demand for medical imaging or equipment solutions in its primary markets. The lack of segment data limits the ability to identify high-growth or declining business lines within the portfolio.

Growth trajectory analysis is constrained by the absence of historical period data in the input. The current revenue figure of $1.02 billion serves as the baseline for valuation, but year-over-year growth rates cannot be calculated. The negative free cash flow and net loss suggest that the company is in a phase of investment or restructuring rather than organic expansion. The market capitalization of $1.05 billion is roughly in line with the revenue base, indicating that investors are pricing in future profitability improvements or asset value rather than current earnings power.

Risk factors include medium liquidity risk and low dilution risk. The key flag of negative net cash after subtracting total debt underscores the refinancing risk associated with the $876.96 million in long-term debt. The low dilution risk is supported by the fact that basic and diluted shares outstanding are identical at 96.08 million, indicating no significant options or convertible securities currently impacting the share count. The primary risk remains the company's ability to service its debt obligations while maintaining positive operating cash flow.

Recent events include analyst coverage updates with a mean price target of $17.17 and a median target of $18.00, suggesting a potential upside from the current market price of $10.89. The mean recommendation of 1.50, with eight strong buy or buy ratings and no holds, indicates strong analyst confidence in the company's future prospects. News observations reference internal reconciler processes for Lumexa Imaging Holdings Inc, but no specific external news events or filing observations are detailed in the input data.

Revenue $252.5M, +3,1% YoY; Operating income −24,0% YoY.

• ▍Revenue $252.5M, +3,1% YoY
• ▍Operating income −24,0% YoY
• ▍Net income +122,3% YoY
• ▍Free cash flow +1 642,4% YoY
• ▍Net margin 0.7%

Revenue $267.7M, +8,0% YoY; Operating income −94,2% YoY.

• ▍Revenue $267.7M, +8,0% YoY
• ▍Operating income −94,2% YoY
• ▍Net income −14,5% YoY
• ▍Free cash flow +2,5% YoY
• ▍Net margin -10.7%

Revenue $1.02B, +7,8% YoY; Operating income +48,6% YoY.

• ▍Revenue $1.02B, +7,8% YoY
• ▍Operating income +48,6% YoY
• ▍Net income +49,9% YoY
• ▍Free cash flow +62,1% YoY
• ▍Net margin -4.6%